Trial Profile

A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib/+Paclitaxel vs Placebo+Paclitaxel as First-line Treatment for Patients With Locally Advanced (Inoperable) or Metastatic TNBC

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 18 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capivasertib (Primary) ; Paclitaxel
Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
Focus Registrational; Therapeutic Use
Acronyms CAPItello-290
Sponsors AstraZeneca; AstraZeneca AB

21 Jan 2025 Planned End Date changed from 21 Feb 2025 to 16 Mar 2026.
21 Jan 2025 Planned primary completion date changed from 21 Feb 2025 to 16 Mar 2026.
16 Jul 2024 Planned End Date changed from 18 Mar 2024 to 21 Feb 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com